Investors
Invest in a patented platform technology
UV Clinical
Join the UV Clinical family - and invest in the future of infection prevention
UV Clinical is backed by 80+ shareholders across 15 countries, including med-tech investors, industry specialists, and strategic partners. Together, they form the UV Clinical family - a strong, international investor community supporting the company’s global scale-up and commercialization. The largest shareholder is CEO, Rolf H. Sprunk-Jansen, who actively leads the company toward FDA clearance and market launch.
Let’s collaborate.
If you are interested in becoming an investor, please contact: